Drug Trial Radar · NCT03747939
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
310
Actual
Start
Dec 31, 2018
Primary completion
Dec 19, 2022
Study completion Jul 5, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.
Conditions
- Arthritis, Psoriatic
Interventions
Apremilast (CC-10004)Drug
Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive "dummy" titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.
Apremilast (CC-10004) PlaceboOther
Subjects randomized to placebo will receive "dummy" dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16Time frame: Week 16
Locations
114 sites in 11 countries. Site status is shown where the registry gives one.
Arizona Arthritis and Rheumatology Research, PLLC
Mesa, Arizona
Covina Arthritis Clinic
Covina, California
Encino Research Center
Encino, California
Providence Medical Foundation
Fullerton, California
Rheumatology Center of San Diego PC
San Diego, California
East Bay Rheumatology Medical
San Leandro, California
Millennium Clinical Trials
Thousand Oaks, California
Robin K Dore MD Inc
Tustin, California
Inland Rheumatology Clinical Trials Inc
Upland, California
Denver Arthritis Clinic PC
Denver, Colorado
Arthritis and Rheumatic Disease Specialties
Aventura, Florida
Clinical Research of West Florida, Inc
Clearwater, Florida
Center for Rheumatology, Immunology, and Arthritis
Fort Lauderdale, Florida
University of Florida College of Medicine
Gainesville, Florida
Integral Rheumatology and Immunology Specialists
Plantation, Florida
Florida Center For Dermatology
Saint Augustine, Florida
Clinical Research of West Florida Inc
Tampa, Florida
Carol and Frank Morsani Center for Advanced Health Care
Tampa, Florida
Baycare Medical Group Inc
Tampa, Florida
North Georgia Rheumatology Group PC
Lawrenceville, Georgia
RC Rsearch Inc
Hinsdale, Illinois
OrthoIllinois
Rockford, Illinois
Graves Gilbert Clinic
Bowling Green, Kentucky
Clinical Trials Management LLC
Metairie, Louisiana
Klein and Associates MD, PA - Cumberland
Cumberland, Maryland
Klein and Associates MD PA
Hagerstown, Maryland
Clinical Pharmacology Study Group
Worcester, Massachusetts
Advanced Rheumatology PC
Lansing, Michigan
Arthritis and Rheumatology Center of Michigan
Lansing, Michigan
Clinical Research Institute of Michigan
Saint Clair Shores, Michigan
Saint Paul Rheumatology PA
Eagan, Minnesota
Arthritis, Rheumatic, and Back Disease Associates
Voorhees Township, New Jersey
New York University Langone Medical Center
New York, New York
University of Rochester
Rochester, New York
Joint and Muscle Research Institute
Charlotte, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Paramount Medical Research and Consulting LLC
Middleburg Heights, Ohio
Arthritis and Osteoporosis Center of Southwest Ohio
Middletown, Ohio
Health Research of Oklahoma
Oklahoma City, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.